Oridonin Attenuates Diabetes‑induced Renal Fibrosis via the Inhibition of TXNIP/NLRP3 and NF‑κB Pathways by Activating PPARγ in Rats
Experimental and Clinical Endocrinology & Diabetes · 01.10.2024 · 132 (10) · 536-544
DOI: 10.1055/a-2322-7438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.10.2024. Verfasst von Gengzhen Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chengdu University of Traditional Chinese Medicine, Chengdu, China. Hauptthemen laut MEDLINE: Carrier Proteins, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Diterpenes, Kaurane. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: the Science and Technology Strategic Cooperation Project of Nanchong City, the National Natural Science Foundation of China, the Project of Sichuan Administration of Traditional Chinese Medicine.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Oridonin possesses remarkable anti-inflammatory, immunoregulatory properties. However, the renoprotective effects of oridonin and the underlying molecular mechanisms in diabetic nephropathy (DN). We hypothesized that oridonin could ameliorate diabetes‑induced renal fibrosis.
Methods
Streptozocin (STZ)-induced diabetic rats were provided with a high-fat diet to establish a type 2 diabetes mellitus (T2DM) animal model, and then treated with Oridonin (10, 20 mg/kg/day) for two weeks. Kidney function and renal fibrosis were assessed. High glucose-induced human renal proximal tubule epithelial cells (HK-2) were also treated with oridonin. The expression of inflammatory factors and fibrotic markers were analyzed.
Results
Oridonin treatment preserved kidney function and markedly limited the renal fibrosis size in diabetic rats. The renal fibrotic markers were inhibited in the oridonin 10 mg/kg/day and 20 mg/kg/day groups compared to the T2DM group. The expression of thioredoxin-interacting proteins/ nod-like receptor protein-3 (TXNIP/NLRP3) and nuclear factor (NF)‑κB pathway decreased, while that of peroxisome proliferator-activated receptor-gamma (PPARγ) increased in the oridonin treatment group compared to the non-treated group. In vitro, PPARγ intervention could significantly regulate the effect of oridonin on the high glucose-induced inflammatory changes in HK-2 cells.
Conclusion
Oridonin reduces renal fibrosis and preserves kidney function via the inhibition of TXNIP/NLRP3 and NF‑κB pathways by activating PPARγ in rat T2DM model, which indicates potential effect of oridonin in the treatment of DN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Chengdu Second people's Hospital, Chengdu, China.
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Förderung
- the Science and Technology Strategic Cooperation Project of Nanchong City
- the National Natural Science Foundation of China
- the Project of Sichuan Administration of Traditional Chinese Medicine
Zitieren
APA
Huang, G., Zhang, Y., Zhang, Y., Zhou, X., Xu, Y., Wei, H., Chen, X., & Ma, Y. (2024). Oridonin Attenuates Diabetes‑induced Renal Fibrosis via the Inhibition of TXNIP/NLRP3 and NF‑κB Pathways by Activating PPARγ in Rats. Experimental and Clinical Endocrinology & Diabetes, 132(10), 536-544. https://doi.org/10.1055/a-2322-7438
Vancouver
Huang G, Zhang Y, Zhang Y, Zhou X, Xu Y, Wei H, et al. Oridonin Attenuates Diabetes‑induced Renal Fibrosis via the Inhibition of TXNIP/NLRP3 and NF‑κB Pathways by Activating PPARγ in Rats. Experimental and Clinical Endocrinology & Diabetes. 2024;132(10):536-544. doi:10.1055/a-2322-7438
BibTeX
@article{Huang2024,
author = {Huang, Gengzhen and Zhang, Yaodan and Zhang, Yingying and Zhou, Xiaotao and Xu, Yuan and Wei, Huiting and Chen, Xian and Ma, Yuerong},
title = {Oridonin Attenuates Diabetes‑induced Renal Fibrosis via the Inhibition of TXNIP/NLRP3 and NF‑κB Pathways by Activating PPARγ in Rats},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2024},
volume = {132},
number = {10},
pages = {536--544},
doi = {10.1055/a-2322-7438}
}
EUVIMED